Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
Neural Regulation01:37

Neural Regulation

43.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.2K
Brainstem01:19

Brainstem

5.8K
The brainstem, located inferior to the brain and superior to the spinal cord, serves as a bridge between the cerebrum and the spinal cord. It plays a vital role in relaying information and controlling critical life functions. It comprises three primary regions: the midbrain, pons, and medulla oblongata.
The Midbrain
The midbrain is located beneath the diencephalon and connects the cerebrum with the lower parts of the brain. The cerebral peduncles are prominent midbrain structures that house the...
5.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiomics and Deep Learning: Bridging Breast Cancer Imaging Phenotypes and Genomic Heterogeneity.

Breast cancer (Dove Medical Press)·2026
Same author

CCR2 Enhances Anti-Intracellular Bacterial Infection by Modulating Macrophage Pyroptosis to Rebalance Th Immune Responses.

Microorganisms·2026
Same author

Human-associated microbial inputs and bacterial-fungal ecological coupling shape antibiotic resistance risk in environmental dust.

Journal of hazardous materials·2026
Same author

Targeting BRD2 and BRD4 inhibit the growth of KSHV-infected immortalized endothelial cells through suppression of LANA translation.

PLoS pathogens·2026
Same author

Targeting Hyaluronan Signaling Overcomes Primary Effusion Lymphoma Cells Resistance to Rapamycin.

Biological procedures online·2026
Same author

Systematic Review of IgA Nephropathy Coexisting With Alport Syndrome.

Kidney international reports·2026
Same journal

Advances in the Application of Brain-Computer Interface-Based Neurofeedback Training in the Rehabilitation of Patients with Major Depressive Disorder.

Neuropsychiatric disease and treatment·2026
Same journal

Second-Generation Long-Acting Injectable Antipsychotics: A Comprehensive Assessment of Effectiveness, Safety, and Cost.

Neuropsychiatric disease and treatment·2026
Same journal

Resting-State EEG Characteristics of Tardive Dyskinesia: Spectral and Network Connectivity Insights.

Neuropsychiatric disease and treatment·2026
Same journal

Efficacy of Adjunctive Lumateperone 42 mg on Anhedonia and Across a Broad Range of Depressive Symptoms in Major Depressive Disorder: Post Hoc Analysis of a Phase 3, Randomized, Placebo-Controlled Trial.

Neuropsychiatric disease and treatment·2026
Same journal

Modifying Neuropsychiatric and Motor Trajectories in Huntington's Disease Through an Integrated Neurobehavioral Clinic Model.

Neuropsychiatric disease and treatment·2026
Same journal

Mini-Review: Allicin as a Potential Neuroprotective Compound in Neurological Disorders.

Neuropsychiatric disease and treatment·2026
See all related articles

Related Experiment Video

Updated: Jan 18, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.4K

Updates on Parkinson's Disease.

Hong Bai1, Wenhui Ma2, Lei Zhu1

  • 1Department of Neurology, No. 926 Hospital, Joint Logistics Support Force of PLA, Kaiyuan, Yunnan, 661699, People's Republic of China.

Neuropsychiatric Disease and Treatment
|September 10, 2025
PubMed
Summary
This summary is machine-generated.

Parkinson's disease research shows new diagnostic tools and therapies targeting alpha-synuclein and LRRK2 offer hope. Advances in neuromodulation and digital phenotyping improve patient care and prediction of motor fluctuations.

Keywords:
Parkinson’s diseasebiomarkersdeep brain stimulationdisease-modifying therapiesgene-environment interactionmitochondrial dysfunctionprecision medicineα-synuclein propagation

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.4K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.0K

Related Experiment Videos

Last Updated: Jan 18, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.4K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.4K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.0K

Area of Science:

  • Neurodegenerative diseases
  • Parkinson's disease pathogenesis
  • Gut-brain axis mechanisms

Background:

  • Parkinson's disease (PD) is a progressive neurodegenerative disorder with increasing global impact.
  • Mechanistic studies implicate alpha-synuclein propagation, mitochondrial dysfunction, and neuroinflammation in PD.
  • Genetic and environmental factors interact to drive disease progression.

Purpose of the Study:

  • To review recent advancements in Parkinson's disease diagnostics and therapeutics.
  • To highlight emerging solutions for biomarker validation and non-motor symptom management.
  • To underscore the shift towards precision-targeted interventions for PD.

Main Methods:

  • Alpha-synuclein seed amplification assays combined with multimodal neuroimaging.
  • Phase II clinical trials for alpha-synuclein immunotherapies and LRRK2 kinase inhibitors.
  • Development of closed-loop deep brain stimulation systems and wearable-enabled digital phenotyping.
  • Application of single-cell spatial transcriptomics to identify neuronal vulnerability.

Main Results:

  • Diagnostic accuracy of 92% for prodromal Parkinson's disease using combined assays.
  • Alpha-synuclein immunotherapies showed a 40% reduction in motor decline.
  • LRRK2 inhibitors demonstrated blood-brain barrier penetration.
  • Closed-loop deep brain stimulation offered 63% superior symptom control.
  • Digital phenotyping achieved 89% prediction accuracy for motor fluctuations.

Conclusions:

  • Current research facilitates a transition from symptomatic treatment to precision-targeted interventions for Parkinson's disease.
  • Biomarker validation across diverse ethnic groups and management of non-motor symptoms remain key challenges.
  • Emerging technologies offer significant potential for improved PD diagnosis, monitoring, and treatment.